Abstract 4418
Background
High field iMRI with integrated neuronavigation system is an advanced diagnostic tool gives information about extent of resection allowing immediate update of neuronavigation parameters after anatomic changes occuring as a result of tumour resection, cerebrospinal fluid evacuation and brain shift.
Methods
20 CNS tumour cases underwent Brain suite MRI prior to surgery, then surgery was done after patient registration in navigation system using iMRI. Preoperative tumor volume was manually segmented, compared with intraoperative volume after first resection attempt and final post operative volume after surgical closure to calculate extent of resection (EOR).Descriptive statistics were used to find mean, SD, frequency, percentage of variables. Normally distributed interval data reported as means by two-sample t- test. Non-normally distributed interval/ordinal data reported as median{inter-quartile ranges} and compared among groups by Wilcoxon exact test to obtain EOR values.
Results
20 cases allocated to two groups (G), 1st in whom surgery was complete after first iMRI and 2nd who underwent further tumour removal. In G1 surgery was terminated in 11 cases after iMRI, GTR in 81.8% cases. iMRI showed subtotal resection(STR) in 18.2% patients but surgery stopped owing to infiltration of eloquent brain. Median preoperative tumour volume was 40.8cm3. Median postoperative tumour volume was 0.81cm3 with a significant p value (<0.001). Median EOR was 98.5% in G1. In G2, 9 of 20 (45%) underwent further resection of residual tumour after post resection iMRI. GTR in 77.7% and STR in 22.3%, because of tumour’s close proximity to eloquent brain area. Median % of tumour resection after the first iMRI was 82.65%. Median EOR from the final postoperative iMRI was 98.3%. GTR increased from 45% to 80 % after use of iMRI. Median % of residual tumour volume significantly decreased from 5.3% to 1.7 % (p value <0.001). Mean control tumour volume was 9.67% and final post operative volume of 4.72% , which is almost half of intraoperative tumour volume (p value <0.001).
Conclusions
iMRI has potential role in maximizing gross total resection rates of CNS tumours which has an overall great prognostic impact.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institutional ethics committee, Max Superspeciality Hospital, New Delhi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3887 - First Real Life Data on Durvalumab after definitive concomitant ChemoRadiotherapy (cCRT) in unresectable Stage (St) III Non-Small Cell Lung Cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) Temporary Authorization of Use (ATU)
Presenter: Virginie Avrillon
Session: Poster Display session 1
Resources:
Abstract
682 - EGFR Inhibitor Versus Chemotherapy as Adjuvant Treatment for Locally-advanced EGFR-mutant Non-Small Cell Lung Cancer
Presenter: Peng Xie
Session: Poster Display session 1
Resources:
Abstract
2509 - Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: interim analysis of a Phase IIIb, multi-national, open-label study
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3300 - First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
Presenter: Daniel SW Tan
Session: Poster Display session 1
Resources:
Abstract
2653 - A combined analysis of two Phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3663 - Impact of plasma EGFR mutation fractions on response to first generation tyrosine-kinase inhibitor in treatment of naïve non-small cell lung cancer patients
Presenter: Xiaohong Wang
Session: Poster Display session 1
Resources:
Abstract
5921 - Definition of an afatinib trough concentration threshold in the treatment of NSCLC
Presenter: Stephane Bouchet
Session: Poster Display session 1
Resources:
Abstract
2852 - A Phase Ib Trial of Neoadjuvant Chemoradiotherapy and Durvalumab(MEDI4736) for Potentially Resectable stage III Non-Small Cell Lung Cancer (NSCLC)
Presenter: Beung chul AHN
Session: Poster Display session 1
Resources:
Abstract
3273 - Low expression of Notch1 and combined Notch1/HES1 are associated with adverse survival factor for limited stage small cell lung cancer
Presenter: Jinsoo Lee
Session: Poster Display session 1
Resources:
Abstract
5141 - Mutational profiling of tumor tissue and sequential plasma illustrates emergent clones during treatment in late stage small cell lung cancer (SCLC)
Presenter: Stephanie Yaung
Session: Poster Display session 1
Resources:
Abstract